Kopran Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 5668.46%
- Ebitda -60.00%
- Net Worth 133.22%
- Total Assets -4.63%
About Kopran Lifesciences
Kopran Lifesciences Limited (KLL) is a Public Limited Indian Non-Government Company incorporated in India on 20 December 2010 and has a history of 14 years and one month. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Professional Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ajit Jain, Surendra Somani, and Susheel Somani serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74120MH2010PLC211125
-
Company No.
211125
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
20 Dec 2010
-
Date of AGM
10 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Kopran Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Susheel Somani
|
Director | 20-Dec-2010 | Current |
|
Ajit Jain
|
Director | 20-Dec-2010 | Current |
|
Surendra Somani
|
Director | 20-Dec-2010 | Current |
Financial Performance of Kopran Lifesciences.
Kopran Lifesciences Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 5668.46% increase in profit. The company's net worth Soared by an impressive increase of 133.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kopran Lifesciences?
In 2023, Kopran Lifesciences had a promoter holding of 99.88% and a public holding of 0.12%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Qualigens Pharma Private LimitedAjit Jain is a mutual person
-
Kopran LimitedSurendra Somani and Susheel Somani are mutual person
-
Hotel Empire LimitedSusheel Somani is a mutual person
-
Claridge Moulded Fibre LimitedSusheel Somani is a mutual person
-
Cmfl Packaging Limited
Susheel Somani is a mutual person
-
Naulakha Impex LlpAjit Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kopran Lifesciences?
Unlock and access historical data on people associated with Kopran Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kopran Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kopran Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
